This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
This information is intended for healthcare professionals based in Ireland.
If you are not a healthcare professional in Ireland, click here
ELIQUIS® Dosing & Switching
ELIQUIS Dosing for your adult patients with NVAF
ELIQUIS Dosing for your adult patients with DVT / PE
Footnotes:
- DVT = Deep Vein Thrombosis NVAF = Non-Valvular Atrial Fibrillation PE= Pulmonary Embolism
Reporting of suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via HPRA Pharmacovigilance at www.hpra.ie
Adverse reactions should also be reported to Bristol Myers Squibb Medical Information on 1 800 749 749 or medical.information@bms.com